Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Haemonetics is expected to report Q4 2026 results before the market opens on Thursday, May 7, with analysts forecasting $1.28 EPS and $337.04M in revenue, and the company guiding FY2026 to $4.90–$5.00 EPS.
• In the prior quarter (reported Feb. 5) Haemonetics beat estimates with $1.31 EPS versus $1.27 expected and $338.97M in revenue, posting a 13.31% net margin and 27.32% return on equity despite revenue declining 2.7% year-over-year.
• Analysts rate the stock a "Moderate Buy" with an average price target of $82.7899.67% institutional ownership.

Haemonetics (NYSE:HAE - Get Free Report) is anticipated to issue its Q4 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $1.28 per share and revenue of $337.0420 million for the quarter. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Parties may review the information on the company's upcoming Q4 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. During the same period in the previous year, the company earned $1.19 earnings per share. The company's quarterly revenue was down 2.7% on a year-over-year basis. On average, analysts expect Haemonetics to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Haemonetics Price Performance

NYSE:HAE opened at $58.99 on Thursday. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a market cap of $2.74 billion, a P/E ratio of 16.25, a P/E/G ratio of 1.18 and a beta of 0.36. The firm's fifty day moving average price is $59.97 and its two-hundred day moving average price is $66.39. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Analyst Ratings Changes

HAE has been the topic of several research reports. Wall Street Zen upgraded shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Saturday, January 10th. Citigroup decreased their price objective on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating on the stock in a report on Wednesday, March 11th. Mizuho decreased their price objective on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Monday, April 13th. Robert W. Baird set a $81.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Finally, Barrington Research set a $94.00 price objective on shares of Haemonetics in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $82.78.

Institutional Investors Weigh In On Haemonetics

Institutional investors have recently modified their holdings of the business. Sivia Capital Partners LLC bought a new stake in shares of Haemonetics in the second quarter valued at about $234,000. Amundi bought a new stake in shares of Haemonetics in the fourth quarter valued at about $222,000. State of Wyoming bought a new stake in shares of Haemonetics in the fourth quarter valued at about $220,000. Caxton Associates LLP bought a new stake in shares of Haemonetics in the first quarter valued at about $216,000. Finally, J.W. Cole Advisors Inc. bought a new stake in shares of Haemonetics in the fourth quarter valued at about $206,000. Institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.